• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Bisson Lori

    8/13/25 9:12:16 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care
    Get the next $AMIX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bisson Lori

    (Last) (First) (Middle)
    21 WATERWAY AVENUE
    SUITE 300

    (Street)
    THE WOODLANDS TX 77380

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Autonomix Medical, Inc. [ AMIX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Option (Right to buy) $26.56 08/11/2025 D 18,862(1) 06/21/2025(1) 06/21/2034 Common Stock 18,862 (1) 47,930 D
    Option (Right to buy) $40 08/11/2025 D 46,680(1) 06/30/2025(1) 06/30/2033 Common Stock 46,680 (1) 1,250(2) D
    Explanation of Responses:
    1. Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation.
    2. Amount represents a revised share amount based on a 1-for-20 reverse stock split from October 25,2024.
    /s/ Trent Smith, Attorney-in-Fact for Lori Bisson 08/13/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AMIX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMIX
    SEC Filings

    View All

    SEC Form 424B5 filed by Autonomix Medical Inc.

    424B5 - Autonomix Medical, Inc. (0001617867) (Filer)

    8/25/25 5:29:33 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form S-1 filed by Autonomix Medical Inc.

    S-1 - Autonomix Medical, Inc. (0001617867) (Filer)

    8/20/25 5:03:30 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Autonomix Medical Inc.

    SCHEDULE 13G/A - Autonomix Medical, Inc. (0001617867) (Subject)

    8/14/25 4:37:23 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Autonomix Medical, Inc. Granted New European Patent for First-in-Class Catheter-Based Technology

    Global patent estate encompasses 80 issued patents and 40 pending patent applications Strengthens strategic position in a multi-billion-dollar market opportunity across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that European Patent Office (EPO) has granted Patent No. 3,697,298 (the ‘298 patent), titled, "Medical Device with Circuitry for Capturing and Processing Physiological Signals." The newly issued ‘298 patent relates to use of its proprietary technolo

    8/20/25 8:30:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.

    Live video webcast on Thursday, August 21st at 1:00 PM ET Register here THE WOODLANDS, TX, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced that Brad Hauser, President and Chief Executive Officer will participate in a virtual investor webinar hosted by Ladenburg Thalmann on Thursday, August 21, 2025 and 1:00 PM ET. The webinar will be moderated by Jeffrey S. Cohen, Managing Director and Director of Equity Research of Ladenburg Thalmann. Following the discussion, there will be a question and answer session. Interested participants may

    8/18/25 9:15:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

    – Live video webcast on Thursday, August 21st at 2:20 PM ET THE WOODLANDS, TX, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Thursday, August 21, 2025 at 2:20 PM ET Presenter: Brad Hauser, President and Chief Executive OfficerRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed

    8/15/25 9:00:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Hauser Bradley

    4 - Autonomix Medical, Inc. (0001617867) (Issuer)

    8/13/25 9:19:59 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Capelli Christopher

    4 - Autonomix Medical, Inc. (0001617867) (Issuer)

    8/13/25 9:16:29 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Klemp Walter V

    4 - Autonomix Medical, Inc. (0001617867) (Issuer)

    8/13/25 9:13:57 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Leadership Updates

    Live Leadership Updates

    View All

    Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

    Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing technology Company remains on track to submit an Investigational Device Exemption ("IDE"), and if approved, will commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX , Dec. 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced th

    12/19/24 8:30:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

    Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman

    6/17/24 4:05:00 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Appoints Jennifer Cook as Chief Business Officer

    Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer. Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated c

    3/19/24 8:45:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    12/3/24 6:17:58 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    11/27/24 10:15:18 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    10/7/24 8:30:24 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care